Citius Oncology Stock Drops 2.8% on Monday

Shares of the oncology company fell amid broader market declines.

Mar. 24, 2026 at 6:20am

Got story updates? Submit your updates here. ›

Citius Oncology, Inc. (NASDAQ:CTOR) saw its stock price decline by 2.8% on Monday, trading as low as $0.62 per share. The company's shares closed at $0.6253, down from the previous close of $0.6431. Trading volume was down 74% from the average session, with just 114,215 shares changing hands.

Why it matters

Citius Oncology is a pharmaceutical company focused on developing targeted oncology therapies. The stock's decline on Monday reflects broader market volatility, as investors assess the company's prospects and the overall performance of the healthcare sector.

The details

The drop in Citius Oncology's stock price comes as the company continues to develop its lead product candidate, LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The company has a market cap of $55.20 million and a debt-to-equity ratio of 0.07.

  • Citius Oncology's stock price fell 2.8% on Monday, March 24, 2026.

The players

Citius Oncology, Inc.

A pharmaceutical company focused on developing targeted oncology therapies, including its lead product candidate LYMPHIR for the treatment of cutaneous T-cell lymphoma.

Got photos? Submit your photos here. ›

The takeaway

The decline in Citius Oncology's stock price on Monday reflects the broader market volatility, as investors continue to assess the company's prospects and the overall performance of the healthcare sector. The company's focus on developing targeted oncology therapies, such as LYMPHIR, will be closely watched by investors as it navigates the regulatory and commercial landscape.